Introduction

Midodrine is a prodrug converted to desglymidodrine, an alpha-1 adrenergic agonist, and is classified as a vasopressor and antihypotensive agent for symptomatic orthostatic hypotension.

Its labelling carries a boxed warning that constrains both prescribing and promotional claims, and our Module 1 content reproduces it in full.

Complete CTD, ACTD and eCTD dossiers, in-vivo bioequivalence data, CoPP, FSC and ICH Zone IVb stability are supplied for MOH registration.

Product Overview Table

Field	Details
Product Name	Midodrine Hydrochloride Tablets
INN / Generic Name	Midodrine hydrochloride
Pharmacological Classification	Vasopressor / antihypotensive
Mechanism (brief)	Prodrug converted to desglymidodrine, an alpha-1 adrenergic agonist producing peripheral vasoconstriction
Indication	Treatment of symptomatic orthostatic hypotension, per approved local labelling
BOXED WARNING	Can cause marked elevation of supine blood pressure (systolic above 200 mmHg). To be used in patients whose lives are considerably impaired despite standard clinical care. Indication rests primarily on a surrogate marker 1-minute standing systolic blood pressure. Clinical benefits, principally improved ability to carry out activities of daily living, have not been verified.
Positioning per Label	Reserved for patients still considerably impaired despite standard clinical care, including support stockings, fluid expansion and lifestyle measures
STOPPING RULE IN LABEL	Reference labelling directs that treatment be continued only for patients who report significant symptomatic improvement
CRITICAL TIMING INSTRUCTION	Last daily dose at least 3 to 4 hours before bedtime, and not after the evening meal. Avoid dosing if the patient will be supine for any length of time.
API Quality	Manufactured using DMF-grade Midodrine Hydrochloride
Pharmacopoeial Standard	USP: Midodrine Hydrochloride Tablets USP
Available Strengths	2.5 mg, 5 mg and 10 mg tablets
Monitoring	Renal and hepatic function assessed before initiating and subsequently, since desglymidodrine is eliminated by the kidneys and the liver has a role in its metabolism
Interaction Counselling	Over-the-counter cold remedies and diet aids can raise blood pressure and may potentiate the pressor effect a counselling point patients routinely overlook
Governing Quality Attribute	Content uniformity at 2.5 mg this is a low-dose product
Shelf Life	36 Months
Manufacturing Facility	WHO-GMP certified general oral solid dosage block, segregated from beta-lactam operations
Dossier Available	Yes, CTD / ACTD / eCTD format

Strengths, Presentation & Specification

Midodrine Hydrochloride Tablets 5 mg

The central strength in the range and the one carrying most volume, used across the usual dosing pattern of two or three doses through the waking day.

Because dosing is confined to daytime hours by the supine hypertension constraint, the dosing schedule for this product is unusually rigid it cannot simply be spread evenly across twenty-four hours, and that shapes both patient counselling and pack sizing.

Midodrine Hydrochloride Tablets 2.5 mg

The initiation and fine-titration strength. At 2.5 mg this is a genuinely low-dose tablet, which makes content uniformity rather than assay the governing quality risk.

It also matters clinically: because the label reserves this product for patients still impaired despite standard care, and directs that treatment continue only where significant symptomatic improvement is reported, careful titration from a low starting dose is part of how the prescriber makes that judgement.

Midodrine Hydrochloride Tablets 10 mg

The higher strength, reducing tablet burden for patients established on larger daily doses.

Typically tendered alongside the other two rather than separately, since patients titrate between them.

An Artwork Point Specific to This Range

Specification & Testing

Content uniformity demonstrated at batch level, with blend uniformity data through granulation and compression at 2.5 mg this is where the product would fail if it were going to

Assay, dissolution and related substances against the declared monograph, with a validated dissolution method

Colourant declarations documented per strength, since the differentiation is part of the product design

Moisture control across shelf life.

Regulatory & Dossier Support

Dossier Availability

CTD (Common Technical Document): ICH-aligned, for regulated and semi-regulated markets

ACTD (ASEAN Common Technical Dossier): Philippines, Vietnam, Myanmar, Indonesia, Cambodia

eCTD: for authorities mandating electronic submission

Module 3 quality documentation including blend and content uniformity data, process validation and dissolution method validation

Stability data: real-time and accelerated under ICH Zone IVb (30°C / 75% RH)

Module 1 labelling reproduces the boxed warning in full, including the surrogate-endpoint statement see Section 5F for why abbreviating it is not an option

Bioequivalence & Biowaiver Position

In-vivo bioequivalence (BE) data against the reference product is the standard route for registration of midodrine hydrochloride tablets, and our submissions carry it.

Whether a BCS-based biowaiver is available in a given jurisdiction depends on the solubility and permeability data recorded in your own dossier rather than on an assumed classification.

BE study data available Analyte selection is worth confirming at protocol stage.

Midodrine is a prodrug converted to desglymidodrine, so which moiety is measured parent, active metabolite, or both should be settled against the applicable guidance before the study is run rather than afterwards

Strength-to-strength biowaiver may be accepted across 2.5 mg, 5 mg and 10 mg where proportional similarity and comparable dissolution profiles are demonstrated, subject to the individual authority    

Comparative dissolution profiles held throughout shelf life

Drug Master File (DMF)

Drug Master File (DMF) reference for the Midodrine Hydrochloride API available for cross-referencing in your registration dossier

API sourced against a qualified vendor with impurity, residual solvent, elemental impurity and particle size characterisation particle size matters for blend uniformity at 2.5 mg

CDSCO / Indian DMF reference accepted by a large number of importing authorities

Manufacturing Compliance

WHO-GMP certifiedmanufacturing facility, audit-ready, with inspection reports shared on an NDA basis

Site Master File (SMF)available for regulatory submissions

Midodrine is neither a beta-lactam nor a cytotoxic and is not subject to international drug control conventions, so no dedicated block is required.

Production runs in a general oral solid dosage block physically segregated from beta-lactam operations, with validated cleaning between products

Low-dose blending controls are the substantive manufacturing question.

At 2.5 mg per tablet, blend homogeneity, API particle size and segregation control during compression govern content uniformity, and these are documented as controlled process parameters rather than release testing outcomes

Colourant handling and changeover controls documented, since three strengths with different colourants run through the same line

Compliant with the requirements of NAFDAC (Nigeria), PPB (Kenya), FDA Philippines, DRAP (Pakistan) and INVIMA (Colombia)

Complete Documentation Package (Per Shipment)

Document	Purpose
Certificate of Analysis (CoA)	Confirms batch quality against the agreed specification
Certificate of Pharmaceutical Product (CoPP / CPP)	Required for MOH registration in most importing countries
Free Sale Certificate (FSC)	Confirms the product is freely sold in the country of manufacture
Method of Analysis (MOA)	Analytical methodology mandatory dossier component
GMP Certificate	Confirms manufacturing site compliance
Stability Data	Real-time and accelerated ICH Zone IVb
BE Study Report or Biowaiver Justification	States route taken, strengths covered and analyte measured
Content Uniformity Data	Batch-level the governing quality attribute at 2.5 mg
Blend Uniformity Data	Through granulation and compression, not only at release
Dissolution Profile Report	Across the physiological pH range
Colourant Declarations	Per strength the differentiation is a design feature
Approved Leaflet, Translated	Carrying the boxed warning and timing instruction in full

What the Boxed Warning Forbids You From Saying

NO OTHER PRODUCT IN THIS SERIES HAS THIS PROBLEM.

Boxed warnings elsewhere in this portfolio warn about harms liver failure, ketoacidosis, fatal intravenous administration.

Midodrine’s does that, and then goes further: it states that the indication rests primarily on a surrogate marker of effectiveness, and that the clinical benefits, principally improved ability to carry out activities of daily living, have not been verified.

A label that discloses the limits of its own evidence sets a ceiling on what marketing may claim, and that ceiling is lower than most commercial teams expect.

The distinction to hold onto is between what was demonstrated and what was hoped for.

What was demonstrated is an increase in systolic blood pressure measured one minute after standing.

What has not been verified is that this translates into patients being better able to carry out their daily activities.

The label states both, and any copy that blurs them is making a claim the registration does not support.

Do not write that the product improves ability to perform daily activities, restores independence, reduces fatigue, or helps patients stand or walk. Each of these describes the unverified benefit

Do write the indication as the label words it treatment of symptomatic orthostatic hypotension and let the prescriber apply it

The reserved positioning is part of the indication, not a caveat. Labelling directs use in patients whose lives are considerably impaired despite standard clinical care, including support stockings, fluid expansion and lifestyle measures.

Copy that presents this as a first-line option misstates the registration

The stopping rule belongs in the leaflet too. Reference labelling directs that treatment be continued only for patients who report significant symptomatic improvement an instruction that most product leaflets in this category do not carry and that this one must

Brief the sales team explicitly. This is the kind of nuance that survives a regulatory review of the artwork and then disappears in a verbal pitch.

The constraint applies to what is said in a meeting as much as to what is printed

We supply the full boxed warning translated for the destination market and will not shorten it to fit a smaller leaflet format.

On this product the warning is unusually long, and the carton has to accommodate it rather than the reverse

Clinical Information & Honest Commercial Assessment

Midodrine is a prodrug converted to desglymidodrine, an alpha-1 adrenergic agonist that produces peripheral vasoconstriction.

It is classified as a vasopressor and antihypotensive agent, and is indicated for the treatment of symptomatic orthostatic hypotension.

Boxed warning. The product can cause marked elevation of supine blood pressure, reported at systolic values above 200 mmHg, and is to be used in patients whose lives are considerably impaired despite standard clinical care.

The indication rests primarily on a surrogate marker of effectiveness, and the clinical benefits have not been verified

The timing instruction is the practical safety control. Patients should take the last daily dose at least three to four hours before bedtime, not after the evening meal, and should avoid dosing if they will be supine for any length of time.

Labelling also notes that nighttime supine hypertension may be further reduced by elevating the head

Monitoring: desglymidodrine is eliminated by the kidneys and the liver has a role in its metabolism, so renal and hepatic function should be assessed before initiating therapy and subsequently as appropriate

Interaction counselling patients overlook: over-the-counter cold remedies and diet aids can elevate blood pressure and may enhance or potentiate the pressor effect.

Patients do not think of these as medicines, and the leaflet has to name them specifically

Market Assessment For Internal Use

Two commercial realities deserve stating internally, neither of which belongs on the page.

First, the label contains a stopping rule: treatment is to be continued only for patients who report significant symptomatic improvement.

That is unusual, and it means this is not a molecule on which to forecast indefinite patient persistence in the way one would for an antihypertensive or a statin.

A proportion of patients started will be stopped by design.

Second, a substantial share of real-world use in several markets is outside the approved indication in settings such as dialysis-associated hypotension and hepatology.

Your sales team will encounter that demand, and they should understand where it comes from.

They must not market to it: promoting an unapproved indication is a serious regulatory exposure in every market this page targets, and it is the single most likely way this product creates a problem for you

Forecast on the approved indication only. Orthostatic hypotension in the populations this product serves is a real but bounded market, and a forecast that quietly assumes off-label volume is a forecast built on something you cannot lawfully support

Channel accordingly. Hospital and specialist neurology, cardiology and geriatric channels rather than broad retail which is where the approved indication is actually diagnosed and managed

Target Export Markets

Africa

Active markets: Nigeria, Kenya, Ghana, Egypt, Tanzania, Ethiopia, South Africa, Côte d’Ivoire

Registration support: NAFDAC (Nigeria), PPB (Kenya), FDA Ghana, TFDA (Tanzania) CoPP and FSC are the primary gatekeeping documents

Demand sits with tertiary neurology, cardiology and geriatric services rather than general distribution

Labelling: English and French artwork available for Anglophone and Francophone Africa

Southeast Asia

Active markets: Philippines, Vietnam, Indonesia, Thailand, Malaysia, Bangladesh

ACTD dossier format supplied as standard mandatory for ASEAN registrations

Stability: ICH Zone IVb data is a prerequisite across this climate zone

Latin America (LATAM)

Active markets: Colombia, Peru, Ecuador, Bolivia, Guatemala, Dominican Republic

USP pharmacopoeial standard preferred; Spanish and Portuguese labelling available

CTD format with local regulatory adaptation, legalisation and apostille support

Middle East & CIS

Active markets: Iraq, Jordan, Yemen, Uzbekistan, Kazakhstan, Azerbaijan

GMP Certificate and CoPP are the primary registration requirements across these authorities

Arabic and Russian labelling available on request

Export Packaging & Supply Chain

Primary Packaging Options

Presentation	Packaging Options
Midodrine Tablets 5 mg	Alu-Alu blister 10×10 and 3×10; HDPE bottle of 100 with induction seal
Midodrine Tablets 2.5 mg	Alu-Alu blister 10×10 and 3×10; HDPE bottle of 100
Midodrine Tablets 10 mg	Alu-Alu blister 10×10; HDPE bottle of 100
Daytime-dosing packs	Configurations reflecting two or three daytime doses rather than a round tablet count

One pack design point is specific to this molecule.

Because the last dose must fall three to four hours before bedtime, dosing is compressed into the waking day rather than spread across twenty-four hours.

A pack sized to a round number of tablets does not map cleanly onto that pattern, and a configuration reflecting the actual daily dose count makes the schedule easier for a patient to follow which matters when the consequence of an ill-timed dose is nocturnal supine hypertension.

Labelling & Customisation

Private labelmanufacturing with your brand name and artwork, subject to unchanged regulatory content

Multi-lingual labelling: English, French, Spanish, Portuguese, Arabic, Russian

Mandatory artwork content: the full boxed warning including the surrogate-endpoint statement, the timing instruction in plain language on the carton face, the supine-hypertension caution, the OTC interaction warning, storage statement and country-specific registration fields

Logistics & Supply

Incoterms: FOB, CIF, CFR, EXW as per buyer requirement

No cold chain required; protect from moisture, light and sustained heat in transit

Lead time: We plan against committed annual forecasts.

Note the stopping rule in when building those forecasts patient persistence on this molecule is lower by design than on a chronic cardiovascular therapy

Why Source Midodrine Tablets From Us?

Boxed Warning Carried in Full, Including the Part Most Suppliers Would Rather Omit: The surrogate-endpoint statement is part of the warning.

We reproduce it, translate it, and refuse to shorten it for carton size, because a leaflet that drops it misrepresents the registration.

Timing Instruction on the Carton Face: The last dose must fall three to four hours before bedtime. The harm it prevents happens at night, long after the leaflet has been put away, so the instruction goes where the patient will see it.

Full Three-Strength Range With Colour Differentiation Preserved: 2.5 mg, 5 mg and 10 mg. Patients hold multiple strengths during titration and are typically elderly; strength differentiation is a safety feature and we will not unify it for brand consistency.

Low-Dose Uniformity Controlled at Source: At 2.5 mg, blend homogeneity and API particle size govern content uniformity. Documented as controlled process parameters, with batch-level data supplied on request.

Straight Advice on What You May Claim: We will tell your regulatory and commercial teams where the promotional ceiling sits on this molecule before artwork is drafted, rather than after a deficiency letter.

WHO-GMP Certified Manufacturing: Segregated general oral solid facility with validated cleaning and colourant changeover controls. GMP certificate and Site Master File (SMF)shared on request.

Frequently Asked Questions

Call to Action

Ready to Source Midodrine Hydrochloride Tablets FDF?

Share your target market, required strengths and expected annual volume, and our export team will respond with the applicable specification, the bioequivalence route that authority requires, dossier format, pack options and pricing.

If you are preparing artwork, ask us for the promotional-claim boundary note first it is easier to draft within it than to revise after a deficiency letter.